Current red blood cell-based therapies face challenges in achieving high levels of therapeutic proteins within the cells, impacting efficacy, and in scaling production using traditional methods that rely on donated stem cells. This limits the potential for treating a wide range of diseases effectively.

Scarlet Therapeutics is developing a platform for generating therapeutic red blood cells (tRBCs) that contain high levels of therapeutic proteins. The company's approach uses proprietary cell lines for production, addressing manufacturing constraints associated with traditional stem cell-based methods. By expressing therapeutic proteins inside the tRBCs, the proteins are shielded from the immune system, potentially enhancing efficacy and enabling targeted treatment for metabolic diseases, cancer, and autoimmune disorders. This technology aims to improve both the effectiveness and scalability of red blood cell-based therapeutics.

Proprietary cell lines engineered for consistent and scalable production of tRBCs

High-level expression of therapeutic proteins within tRBCs for enhanced efficacy

Protection of therapeutic proteins from the immune system via encapsulation within tRBCs

Potential application across a range of diseases, including rare metabolic disorders, cancer, and autoimmune conditions

The primary target audience includes patients with rare metabolic diseases such as hyperammonemia and hyperoxaluria, as well as individuals with cancer and autoimmune disorders who could benefit from targeted protein therapies.